dkishore
08-07-2008, 06:46 AM
In the backdrop of a slowdown in the economy, the pharma sector is gaining favour as a defensive sector to invest in. While the large-caps have traditionally been on the top of the list of most investors, a mid-cap entity seems to be the latest hit. On Monday, dealers were heard pitching for Panacea Biotech to investors ready to put their money in pharma counters.
According to market buzz, the Punjab-based company has been granted a patent for a haemorrhoids drug by the US Patent & Trademark Office. The company would soon be launching the drug in the US and EU markets, dealers claimed. Analysts said the size of anti-haemorrhoids drug market in the US and the EU was in the range of $400-500 million.
According to market buzz, the Punjab-based company has been granted a patent for a haemorrhoids drug by the US Patent & Trademark Office. The company would soon be launching the drug in the US and EU markets, dealers claimed. Analysts said the size of anti-haemorrhoids drug market in the US and the EU was in the range of $400-500 million.